Expression analysis revealed that MTDH expression is significantly higher in melanoma, breast, esophageal, gastric, hepatocellular, endometrial and prostate cancers, renal cell carcinoma, neuroblasoma and malignant glioma cell lines compared with their normal counterparts [12], [15]–[23]. This evidence concerns the gene MTDH and prostate carcinoma.